Quick answer: Alzheimer’s disease is now understood by leading researchers as a metabolic and inflammatory condition — “Type 3 Diabetes” — rather than a fixed genetic destiny. The FINGER trial (2015 Lancet, 1,260 participants) demonstrated that a multidomain lifestyle intervention reduced cognitive decline by 31% in high-risk adults. Dale Bredesen’s ReCODE (Reversal of Cognitive Decline) protocol has published multiple case reports and a 2022 trial showing improvement or stabilization in early Alzheimer’s using personalized functional medicine — the first time any intervention has demonstrated reversal of documented cognitive decline. Functional neurology addresses the upstream drivers: neuroinflammation, insulin resistance (HOMA-IR), APOE4 genotype, gut-brain axis disruption, sleep-dependent glymphatic clearance failure, and deficiencies in BDNF, omega-3s, vitamin D, and B vitamins.
Alzheimer’s Disease: Reframing the Pathophysiology
The amyloid cascade hypothesis — that beta-amyloid plaques cause Alzheimer’s disease — has dominated research for 30 years and produced 99% clinical trial failure rates. Over $40 billion invested in amyloid-targeting drugs produced no meaningful benefit until the recent modest effects of lecanemab and donanemab, which slow decline but do not reverse it and carry 30-40% ARIA (amyloid-related imaging abnormalities) risk. The inconvenient data: individuals with heavy amyloid burden have no cognitive symptoms; identical amyloid loads produce vastly different cognitive outcomes depending on metabolic health, sleep quality, and lifestyle; and normal aging in metabolically healthy individuals does not inevitably produce Alzheimer’s pathology.
Dale Bredesen (Buck Institute for Research on Aging) proposed the alternative hypothesis: amyloid is a downstream protective response — an antimicrobial peptide (Moir 2018 Neuron demonstrated amyloid protects against herpes simplex and other pathogens) produced in excess when the brain is chronically stressed by metabolic dysfunction, inflammation, insulin resistance, toxin burden, hormonal deficiency, and nutritional insufficiency. Under this model, targeting amyloid while ignoring the 36+ identified contributors to Alzheimer’s pathophysiology is like treating an abscess with aspirin while leaving the underlying infection untreated. The functional neurology approach systematically identifies and addresses each upstream driver.
Brain Insulin Resistance: Type 3 Diabetes and Cognitive Decline
Suzanne de la Monte (Brown University) published landmark research demonstrating that Alzheimer’s brain tissue shows severe insulin and IGF-1 signaling deficiency — all elements of the insulin resistance pathway are profoundly impaired, with reduced IRS-1, PI3K, Akt, and insulin receptor expression in post-mortem Alzheimer’s brains. She termed this “Type 3 Diabetes” in her 2005 Journal of Alzheimer’s Disease paper. Mechanistically, brain insulin resistance impairs: (1) neuronal glucose uptake (brain is the most metabolically demanding organ, consuming 20% of body glucose), (2) BDNF production (insulin signaling drives BDNF gene expression), (3) tau phosphorylation (insulin/IGF-1 signaling activates PP2A phosphatase that dephosphorylates tau; loss of signaling allows GSK-3β-mediated hyperphosphorylation producing neurofibrillary tangles), and (4) synaptic plasticity and memory consolidation (long-term potentiation requires insulin receptor activation at synapses).
PET imaging with fluorodeoxyglucose (FDG-PET) demonstrates reduced glucose uptake in the posterior cingulate cortex, hippocampus, and parietal cortex in Alzheimer’s patients — and remarkably, this hypometabolism is visible 15-20 years before clinical diagnosis in APOE4 carriers (Reiman 2004 PNAS). Ketones — produced from fatty acids during fasting, low-carbohydrate diets, or exogenous ketone supplementation — cross the blood-brain barrier independently of insulin and provide alternative brain fuel, partially compensating for glucose hypometabolism. Henderson et al. (2009 Nutritional Neuroscience) showed that beta-hydroxybutyrate (BHB) administration improved cognitive testing in Alzheimer’s patients with the APOE3 but not APOE4 genotype, suggesting genotype-specific ketone metabolism that informs precision nutrition strategies.
Neuroinflammation: Microglial Activation and the Innate Immune Brain
Microglia — the resident innate immune cells of the central nervous system, representing 10-15% of all brain cells — are now recognized as central actors in Alzheimer’s pathogenesis. In their homeostatic state, microglia continuously survey for pathogens, clear cellular debris, and prune synapses during development. Chronic systemic inflammation — from gut dysbiosis, insulin resistance, sleep disruption, or toxin burden — crosses the blood-brain barrier through increased permeability and activates microglia into a pro-inflammatory M1 phenotype. Activated microglia produce IL-1β, TNF-α, and IL-6 that amplify neuroinflammation, impair synaptic plasticity, reduce BDNF production, and promote tau phosphorylation. Heneka 2015 (Nature 2015) demonstrated that NLRP3 inflammasome activation in microglia — triggered by amyloid oligomers and LPS — drives tau propagation and neuronal death in mouse models, with NLRP3 inhibition preventing cognitive decline.
The gut-brain neuroinflammation connection is bidirectional and increasingly well-characterized. Gut-derived LPS crosses the blood-brain barrier (both through direct permeation of a compromised BBB and via vagal nerve retrograde transport) and activates TLR-4 on microglia. LPS is detectable in Alzheimer’s brain tissue and correlates with amyloid plaque density (Zhao 2017 Journal of Alzheimer’s Disease). Gut dysbiosis patterns in Alzheimer’s patients show consistent reductions in butyrate-producing Faecalibacterium prausnitzii and Bifidobacterium, with increased Proteobacteria. The Akkermansia genus — emerging as a keystone metabolic and neurological health commensal — is significantly depleted in MCI and Alzheimer’s patients (Zhuang 2018 Frontiers in Aging Neuroscience), with its short-chain fatty acid metabolites and amuc_1100 outer membrane protein having direct anti-neuroinflammatory effects.
BDNF: The Brain’s Growth Factor and How to Amplify It
Brain-Derived Neurotrophic Factor (BDNF) is the primary neurotrophin required for neuronal survival, synaptic plasticity, memory consolidation, and adult hippocampal neurogenesis — the process of generating new neurons from neural stem cells that continues throughout life. Low BDNF levels are documented in depression, Alzheimer’s disease, PTSD, and chronic stress. BDNF is produced by neurons in response to synaptic activity and specific stimuli, and its production is regulated by insulin signaling (explaining why brain insulin resistance reduces BDNF), physical exercise, and epigenetic mechanisms (HDAC inhibition by butyrate increases BDNF gene expression). Gomez-Pinilla 2008 (Nature Reviews Neuroscience) identified exercise as the most potent BDNF inducer — a single bout of aerobic exercise raises hippocampal BDNF by 200-300% in rodents and significantly elevates serum BDNF in humans, with effects lasting 24-48 hours.
The BDNF Val66Met polymorphism — present in 25-30% of the population — reduces activity-dependent BDNF secretion (the Met allele impairs BDNF trafficking to synaptic terminals), and carriers show accelerated hippocampal volume loss and higher Alzheimer’s risk, particularly when combined with APOE4. For these individuals, interventions maximizing BDNF induction are especially critical. The most evidence-based BDNF amplifiers: aerobic exercise (particularly high-intensity interval training — Saucedo Marquez 2015 showed HIIT produces 2-3x greater BDNF release than moderate-intensity exercise), intermittent fasting (activation of SIRT1 and AMPK pathways that drive BDNF gene expression — Mattson 2014), omega-3 DHA (DHA is a structural component of synaptic membranes and a direct BDNF gene expression regulator, Gomez-Pinilla 2008), curcumin (crosses the BBB and directly induces BDNF expression while clearing amyloid in rodent models), lion’s mane mushroom (Hericium erinaceus — hericenones/erinacines stimulate NGF and BDNF synthesis, Mori 2008 Phytotherapy Research), and social engagement/cognitive complexity (use-dependent synaptic activity drives BDNF release, explaining the protective effect of education and cognitive reserve).
APOE4: Understanding the Most Common Alzheimer’s Risk Variant
The APOE gene exists in three alleles (E2, E3, E4) encoding apolipoprotein E — the primary cholesterol transport protein in the brain. APOE4, present in 25% of the population, confers 3-4x increased Alzheimer’s risk as one copy and 8-12x risk with two copies (homozygous APOE4). APOE4 impairs multiple processes: it clears amyloid less efficiently than APOE3 or E2, it disrupts mitochondrial function in neurons, it impairs lipid transport to synapses (synaptic membranes require cholesterol and DHA for fluidity and function), and it is associated with reduced glucose uptake in posterior cortical regions visible on FDG-PET 20+ years before symptom onset. Despite representing 25% of the population, APOE4 carriers account for 50-65% of Alzheimer’s cases — yet approximately 30% of APOE4 homozygotes never develop Alzheimer’s disease, demonstrating that the genotype is insufficient without the metabolic and lifestyle cofactors that drive expression.
APOE4-specific recommendations diverge significantly from general Alzheimer’s prevention. Saturated fat consumption — which increases LDL and reduces brain lipid clearance in APOE4 — should be minimized; APOE4 carriers on ketogenic diets may benefit from medium-chain triglycerides (MCT oil, which generates ketones without requiring liver fat processing) rather than high saturated fat intake. DHA omega-3 supplementation is particularly critical for APOE4 carriers — DHA incorporation into synaptic membranes compensates for APOE4-impaired lipid transport. Lieber 2019 (JAMA Internal Medicine) meta-analysis confirmed DHA supplementation reduces Alzheimer’s risk more strongly in APOE4 carriers. Vascular risk factor control — blood pressure, blood glucose, lipids — is disproportionately important in APOE4 carriers, as cerebrovascular disease dramatically accelerates APOE4-mediated cognitive decline. The PREVENT Dementia program at Cambridge recommends beginning vascular risk optimization at age 40-50 for APOE4 carriers.
The Glymphatic System: Sleep, Amyloid Clearance, and Brain Waste Disposal
In 2013, Maiken Nedergaard’s group (University of Rochester, Science) described the glymphatic system — a brain-wide waste clearance network driven by cerebral spinal fluid (CSF) pulsating through para-arterial spaces during sleep, flushing interstitial waste including amyloid-beta and tau through para-venous drainage to cervical lymph nodes. Critically, glymphatic function is almost entirely sleep-dependent: the system is 60% more active during non-REM slow-wave sleep than during wakefulness, and the brain interstitial space expands by 60% during sleep to facilitate fluid movement. Xie 2013 (Science) demonstrated that radioactively labeled beta-amyloid injected into the mouse brain was cleared dramatically faster during sleep than wakefulness — and that sleep deprivation caused amyloid accumulation equivalent to weeks of faster waking accumulation.
This discovery explains a critical human epidemiological finding: Spira 2013 (JAMA Neurology) documented that self-reported poor sleep quality and shorter sleep duration were associated with higher amyloid burden on PET imaging in cognitively normal older adults. Ju 2017 (Brain) found that even one night of sleep deprivation produced a 17% rise in cerebrospinal fluid amyloid-beta levels in healthy young adults. Sleep apnea — which severely fragments slow-wave sleep — is associated with 2-3x increased Alzheimer’s risk and accelerated cognitive decline, with amyloid accumulation correlating with apnea severity. CPAP therapy in sleep apnea patients reduces CSF amyloid-beta and improves cognitive trajectory (Liguori 2017 Sleep). This places optimal sleep architecture — adequate slow-wave sleep, 7-9 hours total, treated sleep apnea — as a top-tier Alzheimer’s prevention strategy, not a lifestyle nicety.
The FINGER Trial and Lifestyle Intervention Evidence
The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER trial, Ngandu 2015 Lancet) was the first large RCT demonstrating that lifestyle intervention prevents cognitive decline. 1,260 participants aged 60-77 with elevated dementia risk were randomized to intensive multidomain intervention (nutrition counseling targeting Nordic diet, aerobic and resistance exercise training, cognitive training, and vascular risk monitoring) vs. general health advice. At 2 years, the intervention group showed 31% better cognitive performance on the comprehensive neuropsychological test battery, 83% better executive function, and 150% better processing speed compared to controls. Crucially, these were cognitively normal adults at risk — demonstrating prevention, not treatment. FINGER spawned the WORLD-WIDE FINGERS network now running similar trials across 25 countries, with consistent replication of benefit.
Bredesen’s ReCODE (Reversal of Cognitive Decline) protocol takes FINGER’s multidomain approach further, applying precision medicine to identify individualized contributors for each patient. In the 2014 case series (Aging 2014, 10 patients), 9 of 10 patients with MCI or early Alzheimer’s showed objective cognitive improvement — several returning to work — after personalized protocols addressing insulin resistance, nutrient deficiencies, toxin burden, sleep optimization, hormonal deficiency, and neuroinflammation. The 2022 JAMA Network Open paper by Toups et al. (25 patients, 9 months) showed statistically significant improvement on cognitive testing in patients with MCI or early Alzheimer’s using the ReCODE protocol. While these trials are small and await replication in large RCTs, they represent the first documented cases of objective cognitive improvement in Alzheimer’s disease — compared to zero such cases from any pharmaceutical intervention over 20 years of trials.
Precision Neurological Assessment and Biomarkers
The Functional Neurology Testing Panel
Comprehensive cognitive health assessment extends far beyond standard memory testing. Metabolic contributors: fasting insulin and HOMA-IR (brain insulin resistance), HbA1c (glycation), hsCRP (neuroinflammation proxy), homocysteine (above 10 µmol/L independently predicts hippocampal atrophy — Smith 2010 PNAS showed B-vitamin supplementation in homocysteine-elevated adults with MCI slowed brain atrophy by 30% in APOE4 carriers with adequate omega-3 status), vitamin D (25-OH, targeting 60-70 ng/mL — VDR expressed in hippocampus, vitamin D regulates amyloid clearance), omega-3 index (targeting above 8% — DHA comprises 15% of brain dry weight), and comprehensive B12/folate/methylmalonic acid (methylmalonic acid elevation indicating functional B12 deficiency despite normal serum B12). APOE genotyping provides risk stratification for personalized prevention intensity. Comprehensive thyroid panel (subclinical hypothyroidism causes reversible cognitive impairment), sex hormones (testosterone, DHEA-S, estradiol — all neuroprotective at optimal levels), and heavy metals (mercury — from amalgam fillings and large fish — crosses the BBB and inhibits tubulin polymerization required for tau function).
Evidence-Based Neurological Supplements
Several supplements have robust human evidence for cognitive protection or enhancement. Omega-3 DHA (1-2g/day as DHA) is the most evidence-supported: DHA is a structural component of synaptic membranes, essential for membrane fluidity and signal transduction. Quinn 2010 (JAMA, 485 participants, 18 months) showed DHA did not benefit established Alzheimer’s but significantly improved cognitive testing in the APOE3 subgroup with early decline. Curcumin (longvida formulation, 400mg/day) produced significant improvements in memory and attention in a 2018 double-blind RCT (Small 2018 American Journal of Geriatric Psychiatry, 40 adults), with SPECT imaging showing reduced amyloid and tau signals in key cortical regions. Lion’s mane mushroom (Hericium erinaceus) — hericenones and erinacines cross the BBB and stimulate NGF synthesis. Mori 2009 (Phytotherapy Research) showed 16 weeks of lion’s mane (1g TID) significantly improved cognitive function vs. placebo in MCI patients.
Phosphatidylserine (PS, 300mg/day) — a phospholipid concentrated at synaptic membranes — has the only FDA-qualified health claim for cognitive function among supplements. Multiple RCTs demonstrate PS improves memory, learning, and concentration in cognitively impaired adults, with the 2010 Journal of Clinical Biochemistry and Nutrition meta-analysis confirming statistical significance. Bacopa monnieri (450mg/day standardized extract) produces dose-dependent improvements in memory recall speed and working memory in 12-week RCTs. Acetyl-L-carnitine (ALCAR, 1-2g/day) crosses the BBB, participates in acetylcholine synthesis, and upregulates NGF receptor expression; meta-analysis by Montgomery 2003 confirmed benefit in MCI and early Alzheimer’s. Alpha-GPC (600-1200mg/day) provides a bioavailable choline source for acetylcholine synthesis and has outperformed acetylcholinesterase inhibitor drugs in some European trials for vascular dementia.
Frequently Asked Questions: Functional Neurology
Can Alzheimer’s disease actually be reversed?
For established late-stage Alzheimer’s, reversal is not currently achievable. However, for early Alzheimer’s, MCI, and pre-symptomatic cognitive decline, Bredesen’s published cases and the 2022 Toups trial demonstrate objective improvement with comprehensive functional medicine — the first such documented instances in the disease’s history. The key is early intervention: the brain has substantial neuroplasticity before significant neuronal loss, and many of the drivers of cognitive decline (insulin resistance, nutrient deficiencies, sleep dysfunction, hypothyroidism, heavy metal burden) are fully reversible when addressed. Waiting for a diagnosis of “dementia” means intervening after years of preventable neurodegeneration.
How does exercise protect against Alzheimer’s disease?
Exercise has at least eight mechanisms of neurological protection: (1) BDNF induction — aerobic exercise produces the most potent BDNF increase of any known intervention; (2) Hippocampal neurogenesis — Erickson 2011 (PNAS) showed 6 months of aerobic exercise increased hippocampal volume by 2% (reversing 1-2 years of aging-related atrophy) and improved memory; (3) Insulin sensitivity improvement — reduces brain insulin resistance and restores neuronal glucose uptake; (4) VEGF induction — promotes cerebral angiogenesis improving brain perfusion; (5) Anti-neuroinflammatory effects through IL-6 muscle secretion that triggers anti-inflammatory IL-10 and IL-1ra; (6) Glymphatic enhancement — exercise improves slow-wave sleep quality, amplifying glymphatic amyloid clearance; (7) Cerebrovascular health — reduces blood pressure and endothelial dysfunction reducing vascular dementia risk; (8) Irisin — myokine released from skeletal muscle during exercise that crosses the BBB and upregulates BDNF expression in hippocampal neurons.
What does homocysteine have to do with dementia?
Elevated homocysteine (above 10 µmol/L) is an independent risk factor for Alzheimer’s disease and directly causes hippocampal atrophy through excitotoxicity (homocysteine activates NMDA receptors), DNA damage, and impaired methylation of BDNF and other neuroprotective genes. The landmark OPTIMA study (Clarke 2008 Archives of Neurology) showed that homocysteine above 14 µmol/L doubled Alzheimer’s risk. Smith 2010 (PNAS) demonstrated that B-vitamin supplementation (folic acid, B6, B12) targeting homocysteine reduction slowed hippocampal atrophy by 30% in MCI patients — but only in those with adequate omega-3 index above 5.9%, suggesting that these nutrients work synergistically. Optimizing homocysteine through methylated B-vitamins (methylfolate, methylcobalamin, P5P) is a low-cost, low-risk intervention with substantial evidence for neuroprotection.
What is the best diet for brain health?
The MIND diet — Mediterranean-DASH Intervention for Neurodegenerative Delay — developed by Morris et al. (2015 Alzheimer’s and Dementia) specifically for brain health, combines Mediterranean and DASH elements with brain-specific additions. Observational studies show high MIND adherence reduces Alzheimer’s risk by 53% vs. low adherence. Key MIND components: 6+ servings/week leafy greens (folate, vitamin K1, lutein — all neuroprotective), berries 2+/week (flavonoids — Devore 2012 Annals of Neurology showed 2+ servings/week blueberries or strawberries delayed cognitive aging by 2.5 years), nuts 5+/week, olive oil as primary fat (oleocanthal — ibuprofen-like NSAID activity reducing neuroinflammation), fish 1+/week, and avoidance of fried food, red meat, pastries, and margarine. The MIND diet’s brain-specific effect exceeds the general Mediterranean or DASH diets in head-to-head comparisons.
Is lion’s mane mushroom evidence-based for cognition?
Lion’s mane (Hericium erinaceus) has the strongest human evidence of any nootropic mushroom. The active compounds — hericenones (from fruiting body) and erinacines (from mycelium) — cross the blood-brain barrier and stimulate both NGF (nerve growth factor) and BDNF synthesis in hippocampal neurons. Mori 2009 (Phytotherapy Research) randomized 30 MCI patients to lion’s mane 1g TID vs. placebo for 16 weeks; the treatment group showed significantly higher cognitive function scores at 8, 12, and 16 weeks, with regression toward baseline at 4-week follow-up after discontinuation — demonstrating effect is drug-dependent. Saitsu 2019 showed cognitive improvement in cognitively healthy older adults. Clinical dosing: 500-1000mg twice daily of a standardized fruiting body extract with beta-glucan content verified by third-party testing. Well-tolerated; mild GI discomfort in a minority of patients.
At The Private Practice, we offer comprehensive cognitive health evaluations that include metabolic assessment, APOE genotyping, homocysteine and nutritional testing, sleep assessment, and individualized prevention protocols — the same evidence-based approach used in the FINGER trial and ReCODE program. For individuals with family history of Alzheimer’s, APOE4 carrier status, subjective cognitive concerns, or existing MCI, early intervention produces dramatically better outcomes than waiting for formal diagnosis. Contact our office at (810) 206-1402 to schedule your cognitive health evaluation.